Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis

During the last decade, outbreaks of acute hepatitis C virus (HCV) infection have been reported among human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) in several European countries. To study this emerging infection in MSM in Antwerp, Belgium, we reviewed all cases of newly acquired HCV infection in HIV-positive MSM followed from 2001 to 2009 at the HIV/sexually transmitted infection (STI) reference clinic of the Institute of Tropical Medicine in Antwerp. Newly acquired HCV infection was considered as certain or probable according to local definitions. During the study period, 69 episodes of newly acquired HCV infection (40 certain and 29 probable) were diagnosed in 67 HIV-infected MSM. In only 10 episodes (14%) were the patients symptomatic. The annual incidence of HCV infection in our population of HIV-infected MSM rose steadily from 0.2% in 2001 to 1.51% in 2008, and then peaked to 2.9% in 2009. For 60 episodes (87%), another STI (mainly syphilis and lymphogranuloma venereum) had been diagnosed within the six months before the diagnosis of HCV infection. All but one patient with available genotyping (n=54) were found to be infected with the difficult-to-treat HCV genotypes 1 or 4. Our results therefore demonstrate the rising incidence of HCV infection in HIV-positive MSM in Antwerp, since 2001, which reached an alarming level in 2009. Targeted awareness campaigns and routine screening are urgently needed to limit further HCV spread and its expected long-term consequences.

Download Full-text

A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran

BMC Public Health ◽

10.1186/s12889-020-8175-1 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Masoud Behzadifar ◽

Meysam Behzadifar ◽

Nicola Luigi Bragazzi

Keyword(s):

Systematic Review ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

People Who Inject Drugs ◽

Meta Analysis ◽

Hepatitis C Virus Infection

Download Full-text

Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis

Journal of Medical Virology ◽

10.1002/jmv.24353 ◽

2015 ◽

Vol 88 (3) ◽

pp. 487-497 ◽

Cited By ~ 24

Author(s):

Fabrizio Fabrizi ◽

Vivek Dixit ◽

Paul Martin ◽

Piergiorgio Messa

Keyword(s):

Systematic Review ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Kidney Disease ◽

Meta Analysis ◽

Hiv Positive

Download Full-text

Association of chronic hepatitis C virus infection with an increased risk of lung cancer: A systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e13562 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e13562-e13562

Author(s):

Ben Ponvilawan ◽

Nipith Charoenngam ◽

Pongprueth Rujirachun ◽

Phuuwadith Wattanachayakul ◽

Surapa Tornsatitkul ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Search Strategy ◽

Meta Analysis ◽

Hcv Infection ◽

Increased Risk ◽

Chronic Hcv Infection ◽

Chronic Hcv

e13562 Background: Chronic hepatitis C virus (HCV) infection is associated with increased risk of multiple types of extrahepatic cancer, such as lymphomas, thyroid cancer and renal cancer. However, whether HCV infection also increases the risk of lung cancer is still inconclusive. This systematic review and meta-analysis was performed in order to determine the relationship between chronic HCV infection and lung cancer. Methods: A systematic review was performed using EMBASE and MEDLINE databases from inception to November 2019 with search strategy that represents “hepatitis C virus” and “cancer”. Eligible studies must be cohort studies which include patients with chronic HCV infection and comparators without HCV infection, then follow them for incident lung cancer. Relative risk, incidence rate ratio (IRR), standardized incidence ratio, or hazard risk ratio of this association along with associated 95% confidence interval (CI) from each study were extracted and combined for the calculation of the pooled effect estimate using the random effect, generic inverse variance. Results: 20,459 articles were discovered using the aforementioned search strategy. After two rounds of review, eight studies fulfilled the inclusion criteria and were included into the meta-analysis. Chronic HCV infection was significantly associated with increased risk of lung cancer with the pooled relative risk of 1.94 (95% CI, 1.56 – 2.42; I2 = 87%). Funnel plot was fairly symmetric and not suggestive of presence of publication bias. Conclusions: Chronic HCV infection is significantly associated with a 1.94-fold increased risk in the development of lung cancer compared to no infection.

Download Full-text

Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis

International Journal of Drug Policy ◽

10.1016/j.drugpo.2015.07.004 ◽

2015 ◽

Vol 26 (10) ◽

pp. 911-921 ◽

Cited By ~ 52

Author(s):

Daniel J. Smith ◽

Joan Combellick ◽

Ashly E. Jordan ◽

Holly Hagan

Keyword(s):

Systematic Review ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Disease Progression ◽

People Who Inject Drugs ◽

Meta Analysis

Download Full-text

Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis

Ethiopian Journal of Health Sciences ◽

10.4314/ejhs.v29i1.17 ◽

1970 ◽

Vol 29 (1) ◽

Author(s):

Meysam Behzadifar ◽

Sanaz Heydarvand ◽

Masoud Behzadifar ◽

Nicola Luigi Bragazzi

Keyword(s):

Systematic Review ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Meta Analysis ◽

Random Effect ◽

Random Effect Model ◽

Final Analysis ◽

Hcv Infection ◽

Cochrane Library ◽

And Gender

BACKGROUND: Infection with Hepatitis C Virus (HCV) increases the hepatotoxicity of anti-tuberculosis drugs. The purpose of this systematic review and meta-analysis is to determine the prevalence of HCV infection in patients with tuberculosis (TB).METHODS: PubMed/MEDLINE, ISI/Web of Sciences, CINAHL, EMBASE, the Cochrane Library and Scopus were searched from January 2000 to March 2018. The overall prevalence of HCV in patients with TB was calculated using the random-effect model with 95% confidence interval (CI). To evaluate heterogeneity, I2 test was used. Egger's regression test was utilized to check publication bias.RESULTS: Twenty-one articles were selected for the final analysis based on the inclusion/exclusion criteria. A total of 15,542 patients with TB participated in the studies. The overall prevalence of HCV infection in patients with TB was 7% [95%CI: 6-9]. Subgroup analysis revealed that diagnostic test (P=0.0039), geographical background (P=0.0076) and gender distribution (P=0.0672) were statistically significant moderators. Men had a higher risk for HCV than women (Odds Ratio, OR=2.02; 95%CI: 1.28-3.18).CONCLUSION: The results of this study highlighted the importance of screening HCV in TB patients. Knowing whether HCV is present or not in these patients can be helpful in effectively treating them.

Download Full-text

Distinct Clinical Features and Prognostic Factors in Hepatitis C Virus-Associated Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-Analysis

10.21203/rs.3.rs-472650/v1 ◽

2021 ◽

Author(s):

Minyue Zhang ◽

Fei Gao ◽

Ling Peng ◽

Lijing Shen ◽

Peng Zhao ◽

...

Keyword(s):

Systematic Review ◽

Prognostic Factors ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Clinical Features ◽

Clinical Characteristics ◽

Meta Analysis ◽

Antiviral Treatment ◽

Hcv Infection ◽

Free Survival

Abstract Background: Increasing evidence suggested that hepatitis C virus (HCV) infection was associated with non-Hodgkin’s lymphoma (NHL). However, no clear consensus has been reached about the clinical features and the effective treatment in HCV-associated NHL patients. We therefore performed a systematic review and meta-analysis to explore the clinical characteristics and effect of antiviral treatment or rituximab administration in NHL patients with HCV infection.Methods: PubMed, Embase, Web of Science, and OVID database were searched for eligible studies up to Feb 28, 2021. Hazard ratio (HR) or odds ratio (OR) corresponding to 95% confidence interval (CI) were calculated to estimate outcomes. Publication biases were assessed by Egger's test and Begg's test. Statistical analysis was performed by software RevMan 5.4 and Stata version 15.Results: There were 27 shortlisted articles out of a total of 13368 NHL patients included in the current meta-analysis. Our results demonstrated that NHL patients with HCV infection showed significantly shorter overall survival (OS: HR 1.89; 95% CI 1.42-2.51, P<0.0001) and progress-free survival (PFS: HR 1.58; 95% CI 1.26-1.98, P<0.0001), lower overall response rate (ORR: OR 0.58, 95% CI 0.46-0.73, P<0.00001) and higher incidence of hepatic dysfunction during chemotherapy (OR 5.96; 95% CI 2.61-13.62, P<0.0001) compared with NHL patients without HCV infection. HCV-positive NHL patients exhibited advanced disease stage, elevated level of LDH, high-intermediate and high IPI/FLIPI risk as well as higher incidence of spleen and liver involvement. Moreover, antiviral treatment could prolong survivals (OS: HR 0.38; 95% CI 0.24-0.60, P<0.0001), reduce disease progression [PFS/DFS (disease-free survival): HR 0.63; 95% CI 0.46-0.86, P=0.003] and reinforce treatment response (ORR: OR 2.62; 95% CI 1.34-5.11, P=0.005) in HCV-infected NHL patients. Finally, rituximab administration was associated with a favorable OS while liver cirrhosis and low levels of albumin were inferior prognostic factors of OS for HCV-positive NHL patients. Conclusions: The current study provided the compelling evidence about an inferior prognosis and distinct clinical characteristics in HCV-associated NHL patients. Antiviral treatment and rituximab-containing regimes were shown to be efficacious to improve clinical outcomes of NHL patients with HCV infection.

Download Full-text